News & Updates

Show Multimedia Only

Topical therapy plus microneedling safe, effective in melasma management

03 Apr 2022

Use of microneedling appears to be a beneficial adjunct to topical medications in the treatment of melasma, suggests a recent study.

03 Apr 2022

Pre-AIS RAS inhibitor exposure tied to less severe stroke, fewer bleeding events

03 Apr 2022

Acute ischaemic stroke (AIS) patients receiving blood pressure (BP)-lowering treatment with renin-angiotensin system (RAS) inhibitors before the index event exhibit less severe stroke and develop intracranial haemorrhage less frequently compared with those on non-RAS inhibitors prior to stroke, according to a study.

03 Apr 2022

COVID-19 vaccine for kids: How young can we go?

02 Apr 2022 by

While the mRNA vaccines currently available on the market have gained regulatory nods* for use in children aged 5 or 6 years old**, Moderna’s mRNA-1273 vaccine is setting a “new low” by showing that two 25 μg doses of the vaccine induce a robust immune response in infants/children as young as 6 months to <6 years of age, according to the latest data from the KidCOVE study.

02 Apr 2022

$Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma$

Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma

01 Apr 2022

Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.

01 Apr 2022

Empagliflozin benefits similar between MRA users, nonusers

31 Mar 2022

In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.

31 Mar 2022

Benralizumab reduces asthma exacerbation rates in real-world setting

31 Mar 2022 by

Treatment with benralizumab significantly reduces exacerbation rates in patients with asthma in a real-world setting, according to the ZEPHYR 2 study presented at AAAAI 2022.

31 Mar 2022

Tezepelumab cuts asthma attacks in patients with severe asthma across seasons

30 Mar 2022 by

Not only does tezepelumab reduce asthma symptomatic days, it prevents asthma exacerbations across all seasons in adolescents and adults with severe, uncontrolled asthma, according to the prespecified exploratory analyses of the NAVIGATOR trial presented at AAAAI 2022.

30 Mar 2022